Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Meyers

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Expert Review of Anticancer Therapy|August 13, 2009
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcomaPaul A Meyers
Current Opinion in Oncology|April 13, 2004
High-dose therapy with autologous stem cell rescue for pediatric sarcomasPaul A Meyers
Advances in Experimental Medicine and Biology|June 3, 2020
Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of OsteosarcomaPaul A Meyers
Pediatric Blood & Cancer|October 22, 2015
Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate ExcretionPaul A Meyers
Pediatric Blood & Cancer|August 8, 2023
Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trialsPaul A Meyers
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Systemic therapy for osteosarcoma and Ewing sarcomaPaul A Meyers
Pediatric Blood & Cancer|July 27, 2010
Ionizing radiation: an element of danger in every procedureElizabeth Robbins, Paul A Meyers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2005
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remissionNeyssa Marina, Paul A Meyers
Journal of Pediatric Hematology/Oncology|November 11, 2003
Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specificRichard Gorlick, Paul A Meyers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?Paul A Meyers, Carlos Flombaum
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Expert Review of Anticancer Therapy|August 13, 2009
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcomaPaul A Meyers
Current Opinion in Oncology|April 13, 2004
High-dose therapy with autologous stem cell rescue for pediatric sarcomasPaul A Meyers
Advances in Experimental Medicine and Biology|June 3, 2020
Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of OsteosarcomaPaul A Meyers
Pediatric Blood & Cancer|October 22, 2015
Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate ExcretionPaul A Meyers
Pediatric Blood & Cancer|August 8, 2023
Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trialsPaul A Meyers
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Systemic therapy for osteosarcoma and Ewing sarcomaPaul A Meyers
Pediatric Blood & Cancer|July 27, 2010
Ionizing radiation: an element of danger in every procedureElizabeth Robbins, Paul A Meyers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2005
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remissionNeyssa Marina, Paul A Meyers
Journal of Pediatric Hematology/Oncology|November 11, 2003
Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specificRichard Gorlick, Paul A Meyers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?Paul A Meyers, Carlos Flombaum
Pageof 12